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Acute symptomatic seizures occur in approximately 10-20% of patients with acute intermittent porphyria in relapse, while there are rarer reports of porphyria in people with chronic epilepsy, mostly drug-resistant. The association between epilepsy and porphyria is unclear. Porphyria might be the cause of chronic symptomatic epilepsy (if so, this would be rare or frequently undiagnosed) or there might be a chance association, given that epilepsy is common. Nevertheless, in drug-resistant epilepsy, metabolic causes such as the porphyrias need to be considered, especially when the seizure frequency increases on higher doses of certain antiepileptic drugs (AEDs). Acute porphyric attacks can be potentially fatal and such attacks are usually precipitated, in susceptible individuals, by exposure to commonly used drugs, including certain AEDs. Correctly determining the safety of use of certain drugs in people with porphyria is therefore important. Once the diagnosis of porphyria-related seizures is confirmed, treatment of the porphyria itself will be needed: management will include appropriate selection of a non-porphyrinogenic AED (as the induction of hepatic haemosynthesis by enzyme-inducing AEDs can exacerbate the symptoms of porphyria, or bring on acute attacks). Clinical experience, and findings from experimental systems, using whole animal or cell culture models, have been used to determine porphyrogenicity (the potential of a drug to induce an acute porphyric attack) and to classify drugs as safe or unsafe in freely available drug lists (e.g. http://www.drugs-porphyria.org; http://www.wmic.wales.nhs.uk/pdfs/porphyria/2015%20Porphyria%20safe%20list.pdf). In acute porphyric attacks, seizures can be treated with intravenous diazepam, levetiracetam, or propofol if status epilepticus develops; a single or few seizures may not require AED treatment in the long term, provided the porphyria itself is properly managed. 
Background
The porphyrias form a heterogeneous group of inherited metabolic disorders, each of which results from deficiency of a specific enzyme in the multi-step heme biosynthetic pathway. [1] Variegate porphyria (VP) is an autosomal dominant form of hepatic porphyria associated with disease-predisposing mutations in the gene for protoporphyrinogen oxidase (PPOX). The phenotypic expression of the condition is the result of deficiency of this enzyme, which converts protoporphyrinogen to protoporphyrin in the penultimate step of heme biosynthesis.
In PPOX-deficiency, the gene carrier state is generally clinically quiescent, but symptoms of variegate porphyria can be triggered by exposure to a variety of precipitating factors, including a wide range of commonly-prescribed medications.
Attacks in acute porphyria mainly feature gastrointestinal and neuropsychiatric symptoms. Accumulation of phototoxic porphyrins in the skin may give rise to solar hypersensitivity and bullous dermal lesions. The treatment of epilepsy in acute porphyrias represents a challenge, because many commonly-used antiepileptic drugs strongly induce heme-dependent cytochromes P450 in the liver. In the course of holoenzyme assembly, the demands for heme are met by the liver through acceleration of de novo heme biosynthesis. In PPOX-deficiency, on porphyrogenic challenge the pathway may become overloaded, with resulting accumulation of phototoxic porphyrins, as well as presumably neurotoxic pre-porphyrin intermediates.
Perampanel is a structurally novel, selective non-competitive AMPA receptor antagonist recently approved for the treatment of partial and secondarily generalized seizures in humans. We describe a case of epilepsy in a carrier of variegate porphyria, in which perampanel was tried after safety assessment.
Case presentation
This 44 year-old lady was the product of a normal pregnancy and delivery. Her motor and cognitive development were normal. Onset of seizures was at nine years of age, with a tonic-clonic seizure. She has tried many antiepileptic drugs in the past without We introduced lacosamide, considered safe in porphyria. Unfortunately she developed a skin rash, without associated symptoms of a porphyric crisis. We could not exclude an allergy to lacosamide and it was therefore discontinued.
Perampanel is amongst the newest antiepileptic drugs. To our knowledge, there is no previous report of its use in acute porphyrias and no patient exposure data were available in the National Acute Porphyria Service After discussion with the patient, we started perampanel, with monitoring of urinary porphobilinogen. Her urinary porphobilinogen level pre-treatment and at one and two weeks on treatment were normal. The National Acute Porphyria Service did not recommend further routine urinary monitoring. The dose of perampanel was initially 2 mg nocte and was gradually titrated in increments of 2 mg up to 4 mg daily.
She had an initial improvement in seizure frequency with up to fifteen days without any seizures, compared to daily seizures before perampanel. After about three months, she developed unsteadiness and had difficulty transferring from her wheelchair. This adverse effect required admission to hospital and physiotherapy. The dose of perampanel was subsequently reduced to 2 mg daily. She did not develop any symptoms of acute porphyria while on perampanel during 23 months of treatment.
Discussion
While acute symptomatic generalised seizures are recognized features of acute attacks of porphyria the association between porphyria and drug-resistant epilepsy is less clear, with few reported cases. [2] In the treatment of epilepsy in acute porphyrias, the choice of drugs should be from amongst the non-CYP-inducing antiepileptic drugs [see Box above] so that porphyrogenic acceleration of hepatic heme biosynthesis is avoided. Treatment with the strong CYP-inducers carbamazepine, phenobarbitone, phenytoin, primidone, topiramate, and sodium valproateshould be avoided as far as possible. Tiagabine shows evidence of porphyrinogenicity in in vitro studies using cultured liver cells and may be hazardous.
The use of perampanel in the present case of variegate porphyria and drug-resistant epilepsy was not followed by any clinical or biochemical signs of activation of the disorder. A single observation of tolerance to a drug in a carrier of acute porphyria, however, cannot be taken as proof of non-porphyrogenicity, because of the great variability between carriers, as well as in one carrier over time, in susceptibility to the action of porphyria precipitating agents. Women are more prone than men to attacks of acute porphyria, and in the present case the carrier exposed to perampanel is a female with a history of clinically manifest acute porphyria, indicating that she does not belong to the group of individuals seemingly constitutionally resistant to the phenotypic manifestations of acute porphyria. The circumstance that our patient is potentially vulnerable to porphyrogenic challenge serves to enhance the significance of the observation of her tolerance to perampanel, and helps to validate the in silico assessment of probable non-porphyrogenicity of the drug.
Recently, two cases with drug-resistant epilepsy in non-carriers of acute porphyria have been described in the literature. Both presented in convulsive status epilepticus and were on treatment with perampanel. Both patients were found to have significantly decreased blood levels of concurrent antiepileptic medication (phenytoin, phenobarbital, rufinamide) in comparison with levels prior to perampanel introduction. In one of the cases, further increasing the perampanel dose resulted in a further drop of the phenytoin level. As demonstrated in cultured human hepatocytes and through drug interaction studies, perampanel is weak inducer of CYP2B6 and CYP3A4/5, as well as of uridine 5'-diphospho-glucuronosyltransferase, while drug transporters are not affected. It is therefore conceivable that the increased rate of elimination of the CYP-metabolized co-administered drugs in the reported cases is an effect of the weak CYP-inductive capacity of perampanel. Until more experience is acquired, initial monitoring of urinary porphobilinogen excretion and subsequent clinical vigilance should be routine in the use of perampanel in acute porphyrias, especially with higher dosage regimes. Monitoring of concomitant antiepileptic drug levels is also indicated. The common side effects, nausea and disturbed appetite, would motivate some attention to nutrition of the patient, to reduce risk for potentially porphyrogenic decrease of caloric intake.
